Wilson Frank Anders
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Cabot Corp to Report Q4 FY2026 Results. Cabot Corporation will release its fourth‑quarter and full‑year 2026 operating results on Friday. The announcement follows a period of steady performance and may influence the stock’s near‑term movement. A recent article highlighted the company’s dividend yield of 2.06% and earnings guidance as key factors for investors. The stock is currently trading near its 52‑week low and close to a support level of $74.80.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Novanta Shares Rise Amid Positive Analyst Mentions. Recent reports highlight Novanta as a stock gaining attention from Wall Street, with one article noting its shares skyrocketed alongside other names. The company is currently trading near its 52-week low, despite analysts maintaining a higher average target price. This divergence suggests the market is currently pricing in significant caution regarding the stock's high valuation.
Transaction History
| ALKS | ▲ Buy | Option Exercise | 6,142 | — | 5/21/2026 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,475 | $55K | 5/21/2026 | View on chart |
| CBT | ▲ Buy | Grant | 2,298 | $0 | 1/8/2026 | View on chart |
| NOVT | ▲ Buy | Option Exercise | 1,325 | — | 1/2/2026 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 8,013 | — | 5/31/2025 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,924 | $59K | 5/31/2025 | View on chart |
| CBT | ▲ Buy | Grant | 1,788 | $0 | 1/10/2025 | View on chart |
| NOVT | ▲ Buy | Option Exercise | 1,217 | — | 1/2/2025 | View on chart |
| NOVT | ▲ Buy | Option Exercise | 278 | — | 7/3/2024 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 6,104 | — | 6/29/2024 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,465 | $35K | 6/29/2024 | View on chart |
| CBT | ▲ Buy | Grant | 2,035 | $0 | 1/11/2024 | View on chart |
| NOVT | ▲ Buy | Option Exercise | 464 | — | 1/3/2024 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 5,957 | — | 7/7/2023 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,430 | $43K | 7/7/2023 | View on chart |
| CBT | ▲ Buy | Grant | 1,854 | $0 | 1/12/2023 | View on chart |
| NOVT | ▲ Buy | Option Exercise | 359 | — | 1/3/2023 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 7,585 | — | 6/14/2022 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 695 | $19K | 6/14/2022 | View on chart |
| NOVT | ▲ Buy | Option Exercise | 304 | — | 5/13/2022 | View on chart |
| CBT | ▲ Buy | Grant | 2,254 | $0 | 1/13/2022 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 5,578 | — | 12/2/2021 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,339 | $30K | 12/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Baird Highlights Growth Potential for Alkermes plc (ALKS)
Baird has highlighted Alkermes plc as a company with promising growth potential, citing its pipeline and recent developments. A Yahoo article compares Alkermes to LQDA, discussing which biotech may be more attractive for investors. The stock is currently trading near its 200‑day moving average and close to a key support level of $48.74, while analysts average a target of $56.56.
Baird Highlights Growth Potential for Alkermes plc (ALKS). Baird has highlighted Alkermes plc as a company with promising growth potential, citing its pipeline and recent developments. A Yahoo article compares Alkermes to LQDA, discussing which biotech may be more attractive for investors. The stock is currently trading near its 200‑day moving average and close to a key support level of $48.74, while analysts average a target of $56.56.